This is huge news!
Reminds us of vitraven the isis first ans. approval. Huge BS up then crash !
LOLOL....They are treating a disease with only 400 patients in the US?? How does this make a profit?? ISIS back to 13's tomorrow.
Yeah, just 400 patients @ $295,000 per year per patient. Read the press release and do the math. It's not about one drug approval, it's about the pipeline.
Hope you short it cal-baby ISIS can then use future buyers at a higher price. Thanks for you detailed, informed info. t
Sentiment: Strong Buy
Shorts are trying to escape..........Shhh.....Some may have shorted at much lower levels hoping for a CRL.
Will see $20 soon, lots of publications coming!